EPS for InflaRx N.V. (IFRX) Expected At $-0.40; Emerson Electric Co Has 0.71 Sentiment

August 3, 2018 – By Lena Young

Emerson Electric Co. (NYSE:EMR) Logo

Emerson Electric Co (EMR) investors sentiment decreased to 0.71 in Q1 2018. It’s down -0.24, from 0.95 in 2017Q4. The ratio dived, as 390 hedge funds opened new or increased equity positions, while 553 cut down and sold their holdings in Emerson Electric Co. The hedge funds in our database reported: 427.58 million shares, down from 429.74 million shares in 2017Q4. Also, the number of hedge funds holding Emerson Electric Co in top ten equity positions increased from 17 to 20 for an increase of 3. Sold All: 41 Reduced: 512 Increased: 268 New Position: 122.

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock increased 8.70% or $2.68 during the last trading session, reaching $33.5. About 24,542 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 3, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018

Another recent and important Emerson Electric Co. (NYSE:EMR) news was published by Fool.com which published an article titled: “Why This Internet of Things Stock Soared After Earnings” on August 02, 2018.

Analysts await Emerson Electric Co. (NYSE:EMR) to report earnings on August, 7 before the open. They expect $0.86 EPS, up 26.47% or $0.18 from last year’s $0.68 per share. EMR’s profit will be $541.88M for 20.72 P/E if the $0.86 EPS becomes a reality. After $0.76 actual EPS reported by Emerson Electric Co. for the previous quarter, Wall Street now forecasts 13.16% EPS growth.

Emerson Electric Co. designs and manufactures products, and delivers services to industrial, commercial, and consumer markets worldwide. The company has market cap of $44.91 billion. The companyÂ’s Process Management segment offers systems and software; measurement and analytical instrumentation; valves, actuators, and regulators; industry services and solutions; and digital plant architecture solutions. It has a 25.53 P/E ratio. It also provides consulting services for precision measurement, control, monitoring, asset optimization, and safety and reliability of gas and oil reservoirs and plants.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $1.73 million activity.

The stock decreased 0.03% or $0.02 during the last trading session, reaching $71.28. About 2.85M shares traded. Emerson Electric Co. (EMR) has risen 22.35% since August 3, 2017 and is uptrending. It has outperformed by 9.78% the S&P500. Some Historical EMR News: 15/03/2018 – EMERSON ELECTRIC CO SAYS EMERSON TRAILING THREE-MONTH ORDERS FOR FEB 2018 INCREASED 10 PERCENT – SEC FILING; 21/03/2018 – Emerson Electric Co. vs SIPCO, LLC | FWD Entered | 03/21/2018; 01/05/2018 – EMERSON SEES 2018 EPS $3.10-$3.20, SAW $3.05-$3.15, EST. $3.13; 06/03/2018 – Emerson Chairman and CEO David Farr to Deliver Keynote at CERAWeek by IHS Markit 2018; 18/04/2018 – Textron to sell tools business to Emerson Electric; 05/03/2018 – Emerson College ePoll: Statistical Dead Heat in PA 18th Congressional Special Election; 01/05/2018 – Emerson Electric 2Q Cont Ops EPS 76c; 29/05/2018 – EMERSON ELECTRIC CO – CREDIT FACILITY EXPIRES IN MAY 2023, REPLACES A SIMILAR $3.5 BLN FIVE-YEAR REVOLVING CREDIT FACILITY DATED APRIL 30, 2014; 05/03/2018 Emerson and Total Sign Long-Term Global Agreement for Paradigm Exploration & Production Software Solutions; 18/04/2018 – EMERSON TO BUY TOOLS & TEST EQUIPMENT FROM TEXTRON

Plancorp Llc holds 6.25% of its portfolio in Emerson Electric Co. for 286,349 shares. John G Ullman & Associates Inc owns 411,348 shares or 5.43% of their US portfolio. Moreover, Tide Point Capital Management Lp has 5.27% invested in the company for 1.01 million shares. The Guernsey-based Longview Partners (Guernsey) Ltd has invested 4.92% in the stock. Bush Odonnell Investment Advisors Inc, a Missouri-based fund reported 38,585 shares.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $859.68 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Emerson Electric Co. (NYSE:EMR) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *